<?xml version='1.0' encoding='utf-8'?>
<rss version="2.0">
	<channel>
		<title>OOIR Trends: Clinical Medicine (Medicine, Research &amp; Experimental)</title>
		<description>Aktuelle Paper-Trends im Bereich Clinical Medicine (Medicine, Research &amp; Experimental) von OOIR (mit Titel und Metadaten von Crossref)</description>
		<link>https://ooir.org</link>
		<language>en-us</language>
		<pubDate>Wed, 03 Sep 2025 00:58:49 GMT</pubDate>
		<lastBuildDate>Wed, 03 Sep 2025 00:58:49 GMT</lastBuildDate>
		<item>
			<title>Ultraprocessed or minimally processed diets following healthy dietary guidelines on weight and cardiometabolic health: a randomized, crossover trial</title>
			<link>https://doi.org/10.1038/s41591-025-03842-0</link>
			<description>Feld: Clinical Medicine
Kategorie: Medicine, Research &amp; Experimental
Score: 2860
Autoren: Samuel J. Dicken, Friedrich C. Jassil, Adrian Brown, Monika Kalis, Chloe Stanley, Chaniqua Ranson, Tapiwa Ruwona, Sulmaaz Qamar, Caroline Buck, Ritwika Mallik, Nausheen Hamid, Jonathan M. Bird, Alanna Brown, Benjamin Norton, Claudia A. M. Gandini Wheeler-Kingshott, Mark Hamer, Chris van Tulleken, Kevin D. Hall, Abigail Fisher, Janine Makaronidis, Rachel L. Batterham
Journal: Nature Medicine
Veröffentlicht: 2025-08-04
Abstract: Abstract
          Ultraprocessed food (UPF) consumption is associated with noncommunicable disease risk, yet no trial has assessed its health impact within the context of national dietary guidelines. In a 2 × 2 crossover randomized controlled feeding trial, 55 adults in England (body mass index ≥25 to &amp;lt;40 kg m−2, habitual UPF intake ≥50% kcal day−1) were provided with two 8-week ad libitum diets following the UK Eatwell Guide: (1) minimally processed food (MPF) and (2) UPF, in a random order. Twenty-eight people were randomized to MPF then UPF, and 27 to UPF then MPF; 50 participants comprised the intention-to-treat sample. The primary outcome was the within-participant difference in percent weight change (%WC) between diets, from baseline to week 8. Participants were blinded to the primary outcome. MPF (%WC, −2.06 (95% confidence interval (CI), −2.99, −1.13) and UPF (%WC, −1.05 (95% CI, −1.98, −0.13)) resulted in weight loss, with significantly greater %WC on MPF (Δ%WC, −1.01 (95% CI, −1.87, −0.14), P = 0.024; Cohen’s d, −0.48 (95% CI, −0.91, −0.06)). Mild gastrointestinal adverse events were common on both diets. Findings indicate greater weight loss on MPF than UPF diets and needing dietary guidance on food processing in addition to existing recommendations. Clinicaltrials.gov registration: NCT05627570.
DOI: 10.1038/s41591-025-03842-0
ISSN: 1078-8956
Tag der Erhebung (OOIR): 2025-09-03</description>
			<guid isPermaLink="false">ooir-trend-10.1038/s41591-025-03842-0-2025-09-03-1</guid>
			<pubDate>Mon, 04 Aug 2025 00:00:00 GMT</pubDate>
		</item>
		<item>
			<title>Pig-to-human lung xenotransplantation into a brain-dead recipient</title>
			<link>https://doi.org/10.1038/s41591-025-03861-x</link>
			<description>Feld: Clinical Medicine
Kategorie: Medicine, Research &amp; Experimental
Score: 1363
Autoren: Jianxing He, Jiang Shi, Chao Yang, Guilin Peng, Chunrong Ju, Yi Zhao, Hui Liu, Ping He, Xiaoqing Liu, Zuopeng Zhang, Chuanbao Chen, Dengke Pan, Zifeng Yang, Wenda Guang, Hongtao Li, Zhonghua Chen, Menyang Liu, Hengrui Liang, Weiqing Huang, Kyeongman Jeon, Toyofumi F. Chen-Yoshikawa, A. Justin Rucker, Amos Lal, Nanshan Zhong, Kang Zhang, Xiaoyou Liu, Xin Xu
Journal: Nature Medicine
Veröffentlicht: 2025-08-25
DOI: 10.1038/s41591-025-03861-x
ISSN: 1078-8956
Tag der Erhebung (OOIR): 2025-09-03</description>
			<guid isPermaLink="false">ooir-trend-10.1038/s41591-025-03861-x-2025-09-03-2</guid>
			<pubDate>Mon, 25 Aug 2025 00:00:00 GMT</pubDate>
		</item>
		<item>
			<title>An oral heme oxygenase inhibitor targets immunosuppressive perivascular macrophages in preclinical models of cancer</title>
			<link>https://doi.org/10.1126/scitranslmed.ads3085</link>
			<description>Feld: Clinical Medicine
Kategorie: Medicine, Research &amp; Experimental
Score: 1191
Autoren: Meriem Bahri, Taha Al-Adhami, Emre Demirel, Jit Sarkar, Karen T. Feehan, Joanne E. Anstee, Tik Shing Cheung, Dominika Sosnowska, Chloé A. Woodman, William Macmorland, Dorothy D. Yang, James Rosekilly, Renee Gitsaki-Taylor, Cheryl E. Gillett, Cheryl L. Scudamore, James Spicer, Khondaker Miraz Rahman, James N. Arnold
Journal: Science Translational Medicine
Veröffentlicht: 2025-08-06
Abstract: 
            A subset of perivascular tumor-associated macrophages (PvTAMs) expressing lymphatic vessel endothelial hyaluronan receptor–1 (LYVE-1) relies on heme oxygenase–1 (HO-1) activity to maintain an immunologically cold tumor microenvironment, which suppresses the efficacy of chemotherapy. Consequently, HO-1 inhibition represents a strategy to target immunosuppressive LYVE-1
            +
            PvTAMs and improve therapeutic responses. We developed and characterized KCL-HO-1i, a small-molecule, orally bioavailable HO-1 inhibitor. In chemotherapy-resistant spontaneous murine
            MMTV-PyMT
            breast cancer and subcutaneous MN/MCA1 sarcoma models, targeting the PvTAM function with KCL-HO-1i enhanced chemotherapy effects and sensitized tumors to treatment. KCL-HO-1i combined with chemotherapy promoted an immunologically hot tumor microenvironment characterized by increased infiltration of CD8
            +
            T cells exhibiting effector function. These findings identify KCL-HO-1i as a nontoxic, orally bioavailable small-molecule immunotherapeutic targeting a key subset of protumoral PvTAMs, offering a combinatorial strategy to enhance chemotherapy efficacy in cancer.
          
DOI: 10.1126/scitranslmed.ads3085
ISSN: 1946-6234
Tag der Erhebung (OOIR): 2025-09-03</description>
			<guid isPermaLink="false">ooir-trend-10.1126/scitranslmed.ads3085-2025-09-03-3</guid>
			<pubDate>Wed, 06 Aug 2025 00:00:00 GMT</pubDate>
		</item>
		<item>
			<title>Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: phase 1 AMPLIFY-201 trial final results</title>
			<link>https://doi.org/10.1038/s41591-025-03876-4</link>
			<description>Feld: Clinical Medicine
Kategorie: Medicine, Research &amp; Experimental
Score: 1010
Autoren: Zev A. Wainberg, Colin D. Weekes, Muhammad Furqan, Pashtoon M. Kasi, Craig E. Devoe, Alexis D. Leal, Vincent Chung, James R. Perry, Thian Kheoh, Lisa K. McNeil, Esther Welkowsky, Peter C. DeMuth, Christopher M. Haqq, Shubham Pant, Eileen M. O’Reilly
Journal: Nature Medicine
Veröffentlicht: 2025-08-11
Abstract: Abstract
          Cellular immunity, mediated by tumor antigen-specific CD4+ and CD8+ T cells, has a critical role in the success of cancer immunotherapy by targeting intracellular driver and passenger tumor mutations. We present the final results of the phase 1 AMPLIFY-201 trial, in which patients who completed standard locoregional treatment, with minimal residual mKRAS disease (n = 25, 20 pancreatic cancer and 5 colorectal cancer), received monotherapy vaccination with lymph node-targeting ELI-002 2P, including mutant KRAS (mKRAS) amphiphile-peptide antigens (G12D, G12R) and amphiphile-adjuvant CpG-7909. At a median follow-up of 19.7 months, efficacy correlated with mKRAS-specific T cell responses above or below a threshold 9.17-fold increase over baseline, with median radiographic relapse-free survival not reached, versus 3.02 months (hazard ratio (HR) = 0.12, P = 0.0002) and median overall survival not reached versus 15.98 months (HR = 0.23, P = 0.0099). Seventy-one percent of evaluable patients induced both CD4+ and CD8+ subsets, with sustained immunogenicity. Following ELI-002 2P treatment, antigen spreading was observed in 67% of patients, with increased T cells reactive to personalized, tumor antigens absent from the ELI-002 2P vaccine. Therefore, lymph node-targeting amphiphile vaccination induces persistent T cell responses targeting oncogenic driver KRAS mutations, alongside personalized, tumor antigen-specific T cells, which may correlate to clinical outcomes in pancreatic and colorectal cancer. ClinicalTrials.gov registration: NCT04853017.
DOI: 10.1038/s41591-025-03876-4
ISSN: 1078-8956
Tag der Erhebung (OOIR): 2025-09-03</description>
			<guid isPermaLink="false">ooir-trend-10.1038/s41591-025-03876-4-2025-09-03-4</guid>
			<pubDate>Mon, 11 Aug 2025 00:00:00 GMT</pubDate>
		</item>
		<item>
			<title>Interplay of genetic predisposition, plasma metabolome and Mediterranean diet in dementia risk and cognitive function</title>
			<link>https://doi.org/10.1038/s41591-025-03891-5</link>
			<description>Feld: Clinical Medicine
Kategorie: Medicine, Research &amp; Experimental
Score: 828
Autoren: Yuxi Liu, Xiao Gu, Yanping Li, Fenglei Wang, Chirag M. Vyas, Cheng Peng, Danyue Dong, Yuhan Li, Yu Zhang, Yin Zhang, Oana A. Zeleznik, Jae H. Kang, Molin Wang, Frank B. Hu, Walter C. Willett, Olivia I. Okereke, A. Heather Eliassen, Peter Kraft, Meir J. Stampfer, Dong D. Wang
Journal: Nature Medicine
Veröffentlicht: 2025-08-25
DOI: 10.1038/s41591-025-03891-5
ISSN: 1078-8956
Tag der Erhebung (OOIR): 2025-09-03</description>
			<guid isPermaLink="false">ooir-trend-10.1038/s41591-025-03891-5-2025-09-03-5</guid>
			<pubDate>Mon, 25 Aug 2025 00:00:00 GMT</pubDate>
		</item>
	</channel>
</rss>